发布求助
文献互助 智能选刊 最新文献

Idrugs最新文献

筛选
英文 中文
The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics. 个性化医学基因组学中癌症基因组测序的临床潜力和挑战。
Idrugs Pub Date : 2010-11-01
Nicole Cloonan, Nic Waddell, Sean M Grimmond
{"title":"The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.","authors":"Nicole Cloonan,&nbsp;Nic Waddell,&nbsp;Sean M Grimmond","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Next-generation sequencing is revolutionizing the way in which genomic-scale biological research is performed, and its effects are beginning to be translated medically. Large-scale international collaborations for the comprehensive sequencing of the genome, epigenome, and transcriptomes of cancers and corresponding 'normal' (germ-line) DNA are heralding the start of personalized medical genomics. The promise of eliminating conjecture when determining treatment approaches is certainly appealing for both patients and clinicians; however, several major issues must be resolved before next-generation sequencing will be adopted as a routine clinical tool for patients. This feature review explores the clinical potential and challenges of studying cancer genomes for personalized medical genomics.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"778-81"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: Part 1. 转移与肿瘤微环境:转移研究学会- aacr联合会议-转移研究:第一部分。
Idrugs Pub Date : 2010-11-01
Suzanne A Eccles
{"title":"Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: Part 1.","authors":"Suzanne A Eccles","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment. This conference report highlights selected presentations on angiogenesis biomarkers, vessel stabilization, genetic determinants of site-specific metastasis and metastasis suppressor genes, including nm23 and KiSS1.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"765-7"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene Based Vaccines: Optimising Development and Delivery - A marcus evans Conference. 基于基因的疫苗:优化开发和交付-马库斯·埃文斯会议。
Idrugs Pub Date : 2010-11-01
Hideki Garren
{"title":"Gene Based Vaccines: Optimising Development and Delivery - A marcus evans Conference.","authors":"Hideki Garren","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Gene Based Vaccines: Optimising Development and Delivery conference, held in Vienna, included topics covering new therapeutic developments in the field of gene-based vaccines. This conference report highlights selected presentations on gene-based vaccine delivery systems, anti-vector immunity in such vaccines, gene-based influenza vaccines, prime-boost strategies for influenza vaccines, DNA vaccines for the prevention of malaria, considerations in DNA vaccine manufacturing, and the ImmunoBody DNA vaccine technology from Scancell.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"759-61"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1. 抗菌药物与化疗科学会议-第50届年会-有前景的新药研究:第1部分。
Idrugs Pub Date : 2010-11-01
Karen Walker
{"title":"Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.","authors":"Karen Walker","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the dicationic porphyrin derivative XF-73 (Destiny Pharma), the tetracycline analog TP-434 (Tetraphase Pharmaceuticals), an elongation factor Tu inhibitor (Novartis Institutes for BioMedical Research), the dihydrofolate reductase inhibitor Rx-101005 (Trius Therapeutics), SII RMab, a fully human mAb to rabies glycoprotein (Massachusetts Biologic Laboratories/Serum Institute of India), the oral lipopeptide CB-183315 (Cubist Pharmaceuticals) for the treatment of Clostridium difficile-associated diarrhea, the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor LMV-601 (Lumavita), and DS-003 (International Partnership for Microbicides), a small-molecule Gp120 inhibitor.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"743-5"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Chemistry - XXIst International Symposium. 药物化学第21届国际学术研讨会。
Idrugs Pub Date : 2010-11-01
Danny Chan
{"title":"Medicinal Chemistry - XXIst International Symposium.","authors":"Danny Chan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The XXIst International Symposium on Medicinal Chemistry from the European Federation of Medicinal Chemistry (EFMC-ISMC), held in Brussels, included topics covering new therapeutic developments in the field of medicinal research. This conference report highlights selected presentations on therapies for neuropathic pain, cognitive disorders, cancer and infection. Investigational drugs discussed include the anticancer imidazole derivative IRC-083927 (Ipsen), the HCV protease inhibitor TMC-435 (Tibotec Pharmaceuticals) and the tuberculosis therapy bedaquiline (Tibotec Pharmaceuticals).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"749-52"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Japan Biotech Forum: London 2010. 日本生物技术论坛:伦敦2010。
Idrugs Pub Date : 2010-11-01
Asma Al-Shamahi
{"title":"Japan Biotech Forum: London 2010.","authors":"Asma Al-Shamahi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"756-8"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 2. 抗菌药物与化疗科学会议-第50届年会-有前景的新药研究:第二部分。
Idrugs Pub Date : 2010-11-01
Karen Walker
{"title":"Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 2.","authors":"Karen Walker","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the chitin synthase inhibitor nikkomycin Z (Valley Fever Solutions/University of Arizona), the glycosylphosphatidylinositol biosynthesis inhibitor E-1210 (Eisai), the β-1,3-d-glucan synthesis inhibitor MK-3118 (Merck & Co/SCYNEXIS), the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals), and the anti-inflammatory nanoemulsion NB-003 (NanoBio).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"746-8"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
European College of Neuropsychopharmacology (ECNP) - 23rd Congress. 欧洲神经精神药理学学院(ECNP)第23届代表大会。
Idrugs Pub Date : 2010-11-01
David P Finn
{"title":"European College of Neuropsychopharmacology (ECNP) - 23rd Congress.","authors":"David P Finn","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 23rd Congress of the European College of Neuropsychopharmacology (ECNP), held in Amsterdam, included topics covering new therapeutic developments in the field of neuropsychopharmacology. This conference report highlights selected presentations on potential psychotropic drug targets, the relationship between psychiatric disorders and pain, treatments for depression and anxiety disorders, the role of glucocorticoid receptors in memory consolidation, and the use of anticonvulsants in impulse disorders.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"753-5"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. 利西瓦坦，一种非肽抗利尿激素V2受体拮抗剂，用于口服治疗低钠血症。
Idrugs Pub Date : 2010-11-01
Jalal K Ghali, Hammam D Zmily, Jareer O Farah, Suleiman Daifallah
{"title":"Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.","authors":"Jalal K Ghali,&nbsp;Hammam D Zmily,&nbsp;Jareer O Farah,&nbsp;Suleiman Daifallah","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure. Arginine vasopressin, the native V2 receptor ligand, stimulates water reabsorption via activation of V2 receptors that are expressed in the collecting ducts of the kidney. In preclinical studies, lixivaptan displayed competitive antagonist activity at V2 receptors in vitro, and increased urine volume and decreased urine osmolality in rats and dogs. The therapeutic benefits of lixivaptan are being evaluated in patients with conditions that are associated with water excess and hyponatremia. Phase II clinical trials in patients with congestive heart failure, liver cirrhosis with ascites or syndrome of inappropriate antidiuretic hormone have demonstrated that, unlike traditional diuretics, lixivaptan increases water clearance without affecting renal sodium excretion or activating the neurohormonal system. Administration of lixivaptan in combination with the diuretic furosemide has been tested in rats as well as in trials in healthy volunteers, in which the two agents were well tolerated. Ongoing phase III trials will determine the role of lixivaptan in the management of hyponatremia, especially when associated with heart failure.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"782-92"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. Aleglitazar是一种PPARα和PPARγ双重激动剂，可用于口服治疗2型糖尿病。
Idrugs Pub Date : 2010-11-01
Beata Lecka-Czernik
{"title":"Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.","authors":"Beata Lecka-Czernik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>PPARγ and PPARα are nuclear receptors mainly involved in the regulation of glucose homeostasis and lipid levels, respectively. Aleglitazar, being developed by Roche Holding, is a dual agonist for PPARγ and PPARα for the potential simultaneous treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus (T2DM). In preclinical studies, aleglitazar decreased non-fasted glucose levels, increased glucose clearance and improved insulin resistance, while also increasing HDL-cholesterol and decreasing LDL-cholesterol levels in serum. In phase I and II clinical trials in patients with T2DM, aleglitazar demonstrated beneficial antidiabetic activities and had a higher antihyperglycemic efficacy than pioglitazone (a PPARγ agonist). Aleglitazar improved the lipid profile in patients and decreased levels of cardiovascular markers of inflammation and clotting. The observed adverse events were characteristic of either PPARγ or PPARα agonists; however, when compared to pioglitazone-PPARγ-mediated effects, such as edema and weight gain, these were less severe. PPARγ-mediated adverse events on bone have not been measured and should be addressed in the future. The PPARα-mediated adverse effects on renal function are of concern and are a primary endpoint of ongoing phase II clinical trials in patients with T2DM. A phase III clinical trial was also ongoing in patients with T2DM who had recently experienced a cardiac event.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"793-801"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信